-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Historical Evolution
December 2021
Sales of the anti-diabetic raw material metformin hydrochloride exceeded 100 million for the first time.
September 2021
Awarded honorary titles such as Specialized, Refined, and Unique Enterprise of Shandong Province and Gazelle Enterprise of Shandong Province.
December 2019
The hypoglycemic drug ingredient, Gliclazide, achieved over 100 million in revenue for the first time as a single product.
July 2019
Shandong Linyi Pharmaceutical Co., Ltd. became a wholly-owned subsidiary.
October 2017
The first digital factory (Factory 4) has officially started production, marking a new stage in digital transformation and upgrading.
March 2016
Koyuan Pharmaceutical successfully listed on the NEEQ
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline